Sentences with phrase «patients completed the study»

Ten patients completed the study.

A total of 98 % of patients completed the study treatment.

88 % of patients completed the study.

Not exact matches

We have now completed several health studies in partnership with the Geisinger Health System, which provides primary care to over 450,000 patients in Pennsylvania, including many residing in fracking areas.

ALKS 3831: Enrollment completed for ENLIGHTEN - 2, a six - month weight study compared to olanzapine in patients with stable schizophrenia.

In parallel, adjudication will be completed for all MACE which occurred during the study, including adjudication for certain events which, per protocol, can not be finally adjudicated until patients complete their final site visit and results are available from certain non-invasive diagnostic testing conducted during such site visits.

Final patient visits will be followed by completing data entry for the more than 35,000 patient years of study in REDUCE - IT, and typical database quality control measures, known as cleaning.

In March 2018, patients in the study began to complete their final clinical site visits, a key step towards study completion.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The company's leading program, a differentiated PPAR gamma agonist (MIN - 102) that has multiple CNS indications, has successfully completed a phase 1 clinical trial and is ready to move into a phase 2/3 study with adult AMN patients.

Such trials should be conducted in varied populations and settings and include longer periods of restricted exposure to pacifiers than have been examined thus far.13 Until such studies can be completed, it is important that breastfeeding support and education be incorporated into prenatal obstetric and early pediatric patient encounters.

«The findings are significant because they can influence how patients with aphasia are treated to ensure a more complete recovery,» said Chaleece Sandberg, assistant professor of communication sciences and disorders at Penn State and principal investigator of the study.

For the study and to quantify the socioeconomic burden of this disease, the researchers conducted a web - based survey (674 out of 956 individuals completed the survey) to characterize the patient and caregiver experience with FTD - related resource use, health - related quality of life, and per - patient annual costs.

While Grob's study is not complete — he has tested 11 out of a projected 12 volunteers — patients seemed to have positive experiences.

The study seeks male and female patients ages 18 to 65 who recently experienced a complete cervical spinal cord injury at the neck that resulted in tetraplegia, the partial or total paralysis of arms, legs and torso.

«One previous study has shown that a large percentage of patients who are diagnosed as having complete paraplegia may still have some spinal nerves left intact,» Nicolelis said.

In studying this patient's progress, Khoruts was initially surprised to find that there was a nearly complete replacement of the woman's microbial flora with her husband's microbes.

Researchers conducted a meta - analysis of 186 studies of patients seeking help for mental health issues that examined whether they accepted the treatment that was recommended and if they did, whether they completed it.

In the new study, scientists from the NIH's National Institute of Allergy and Infectious Diseases (NIAID) and their colleagues sequenced the complete genomes of ST258 K. pneumoniae strains collected from two patients in New Jersey hospitals.

But, he says, for a device like this, researchers will need to tweak the technology, recruit more patients, run a one - or two - year - long study and complete another year or two of follow - up — plus time to review the data and seek approval from the FDA.

The study examined 328 patients with cervical cancer and 1,312 controls, matched on age and decade, who enrolled in a hospital - based case - control study drawn from 26,831 patients who received treatment at Roswell Park Cancer Institute and completed the Patient Epidemiology Data System questionnaire between 1982 and 1998.

Researchers studied 315 randomized patients, who all completed the five year - follow - up.

Researchers have published a study examining racial and ethnic influences in the outcomes of patients with motor complete spinal cord injury (SCI).

In total, 245 physicians completed both pre - and post-CT surveys for 1,280 patients who comprised the study group.

Among the evaluable patients in the newly reported phase II study, 23 (58 %) achieved complete response to the combination within four cycles, and 6 (15 %) had a partial response.

After a median follow - up of 11 months, 11 of the 13 patients who responded remain on the study, including one patient who had non-small cell lung cancer (NSCLC) with a ROS1 gene fusion who has had a complete response that has been maintained for more than two years.

The second cohort of 140 patients with human leukocyte antigen - matched unrelated donor transplants completed enrollment in November 2017, with data expected from this randomized double - blind arm of the study in the next six months.

In the study by Lisa E. Ishii, M.D., M.S.H., of Johns Hopkins University, Baltimore, and her coauthors, 473 casual observers completed a survey that included images of 13 unique patients before and after surgery, although survey participants were unaware of patients» surgery status.

The study recruited 156 patients with ALS and 128 control patients for comparison; 101 patients with ALS and 110 controls had complete demographic and pollutant data.

The primary outcome measured for the study was cognitive deterioration among patients who completed assessments at study entry and 3 months.

One of the most impressive and unexpected findings of the study is that two of the patients who benefited from the spinal stimulation had complete motor and sensory paralysis.

«Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied.»

A Canadian research team led by Dr. Mark Ware from the Research Institute of the McGill University Health Centre (RI - MUHC) in Montréal has completed a national multicentre study looking at the safety of medical cannabis use among patients suffering from chronic pain.

The aim of the current study was to examine whether complete ablation by performing RDN in accessory renal arteries, in addition to the main renal arteries, would influence blood pressure even more in patients with rHTN.

The 97 patients studied had severe sleep apnea, with a median of 48 apnea - hypopnea events (complete or partial interruptions of breathing) per hour on standard testing in the sleep laboratory.

The study's first six patients received 5 x 108 cells — more than 500 million of the modified cells — as a fractionated dose given over the course of three days, and five patients achieved a complete remission and one patient had a partial response to the therapy.

«With this study the investigators show that their findings about a motor complete patient regaining movement, as published three years ago in The Lancet, were not an anomaly,» said Susan Howley, executive vice president for research at the Christopher & Dana Reeve Foundation.

Among 382 randomized patients, 380 completed the study.

In a study of 30 patients who received CTL019 for three different types of non-Hodgkin lymphoma, the researchers found that 59 percent of patients responded to the therapy (17 of 29, 15 of who experienced complete remissions of their disease).

Overall, 351 patients (77 percent) completed treatment with the study drug with valid 12 - week N - terminal pro-B-type natriuretic peptide (NT - proBNP) levels and no major protocol deviation.

The study reports that 13 of 34 (38 %) patients who achieved complete remission have remained disease - free for over five years and may be cured.

In this study, the team imaged 43 patients undergoing ECT at three time points, before beginning treatment, after the second ECT session and within one week of completing treatment, resulting in 129 brain scans.

March 23, 2006 Efforts to replicate controversial diabetes therapy bring partial success An effort by researchers at the University of Chicago to confirm the results of a high - profile study that brought extraordinary hope to diabetes researchers and patients worldwide has met with considerable, but not complete, success.

According to a study completed at the Helsinki University Hospital Department of Neurosurgery, even patients over the age of 75 may recover from severe traumatic brain injury.

UNITY has completed a rigorous screening and preclinical testing process of candidate drugs, discovered in this study, and is launching a new clinical trial to assess its first drug, for patients with osteoarthritis of the knee this year.

The study consisted of an analysis of 2011 Medicare claims data (Part A hospital and Part B physician) for a random, nationally representative sample of family medicine and internal medicine physicians completing residency between 1992 and 2010 with Medicare patient panels of 40 or more patients (2,851 physicians providing care to 491,948 Medicare beneficiaries).

The phase 1 / 2a study of IONIS - HTTRx was recently completed and showed the therapy to be safe and well - tolerated but also showed it's ability to reduce the level of mutant huntingtin in a dose dependent manner in Huntington's Disease patients.

More than 75 percent of patients had completed the dose escalation when study data were analyzed.

Systematic lymphadenectomy in patients with advanced ovarian cancer and complete resection does not improve progression - free or overall survival, and should be omitted, according to results of a new study.

«Upfront surgery aiming at macroscopic complete resection is the goal in patients with primary advanced ovarian cancer,» said Philipp Harter, MD, PhD, of the Kliniken Essen - Mitte in Germany, during his presentation of the LION study (abstract 5500) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.